Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., He...(aligenat a time the company is moving ra...),Health

Date:7/23/2008

aligen at a time the company is moving rapidly toward the clinical development stage," said Tim Mills, Ph.D., Taligen's chairman and a managing director with Sanderling Ventures. "I look forward to working with her as we implement our corporate growth plan to build a company focused on the development of a pipeline of protein therapeutics intended for the treatment of diseases where complement dysregulation is implicated."

In January Taligen closed the first tranche of a $65 million Series B financing led by Alta Partners and Clarus Ventures with participation from existing investors Sanderling Ventures, Tango and High Country Venture. The financing is expected to enable Taligen to implement its growth plan and advance multiple product candidates to the proof-of-concept stage.

"I am thrilled to join and lead the Taligen team," said Dr. Celniker. "The complement system is emerging as a critical area for drug development. Taligen's founders discovered and validated the importance of the alternative pathway as an amplification loop in the inflammation process. Based on this expertise, the company has designed protein therapeutics that are intended for the treatment of a wide range of orphan and large indications. These programs are cutting-edge and should be very appealing to prospective corporate partners. With the company's expertise, protein therapeutic development candidates and strong financial backing, Taligen is well-positioned to implement its corporate growth plan."

About Taligen Therapeutics

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that are designed to modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amp
'/>"/>

SOURCE Taligen Therapeutics Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
2. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
3. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
4. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
5. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
6. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
7. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
8. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
9. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Silence Therapeutics Announces Board Changes
11. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial